NCT00380991

Brief Summary

The purpose of this study is to demonstrate the absence of potential irritation (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd Delicata (new fragrance of Dermacyd)

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at below P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2006

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

September 25, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 27, 2006

Completed
Last Updated

May 16, 2008

Status Verified

May 1, 2008

First QC Date

September 25, 2006

Last Update Submit

May 15, 2008

Conditions

Hygiene

Outcome Measures

Primary Outcomes (1)

  • score evaluation of the cutaneous reaction, preconized by International Contact Dermatitis Research Group (ICDRG)

Interventions

lactoserumDRUG

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Phototype Skin I,II, III and IV
  • Integral skin test in the region;

You may not qualify if:

  • Lactation or gestation
  • Use of Antiinflammatory and/or immunosuppression drugs
  • Personal history of atopy;
  • History of sensibilization or irritation for topic products;
  • Active cutaneous disease;
  • Use of new drugs or cosmetics during the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sanofi-aventis

São Paulo, Brazil

Location

MeSH Terms

Interventions

lactoserum

Study Officials

  • Jaderson Lima

    Sanofi

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 25, 2006

First Posted

September 27, 2006

Study Start

May 1, 2006

Last Updated

May 16, 2008

Record last verified: 2008-05

Locations

BR(1)